- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03891303
Allogenic Blood Transfusion During Elective Open Abdominal Aortic Surgery
Allogenic Blood Transfusion During Elective Open Abdominal Aortic Surgery and Its Predictors: a Retrospective Database Study at a Tertiary Hospital in Croatia
Open surgery on the abdominal aorta is a high risk procedure associated with an intravascular volume blood loss and thereby, with high requirement for blood and blood product transfusion.
The aim of this study was to establish the rate for allogenic blood transfusion (ABT) during elective open abdominal aortic surgery and find parameters associated with ABT requirements.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Two distinct clinical entities affect the abdominal aorta: abdominal aortic aneurysm (AAA) and aortoiliac occlusive disease (AIOD). These are multifactorial vascular disorders caused by complex genetic and environmental factors. Older patients with more comorbidity are often affected. Open abdominal aortic surgery is associated with high mortality rate. Even in specialised institutions it varies from 2 to 5%. Similar results can be compared to mortality for coronary artery bypass grafting. This reflects the complexity of the surgery and the general health of those patients. It is associated with intravascular volume blood loss and, thereby, with a high requirement for blood and blood products transfusion. Allogenic blood transfusion (ABT) has been associated with an increased risk of tumour recurrence, postoperative infection, acute lung injury, perioperative myocardial infarction, postoperative low-output cardiac failure, and increased mortality.
In the last decades, multiple strategies have been undertaken to prevent massive intraoperative blood loss during elective surgery and allogenic blood transfusion requirement. One of the method advocates a preoperative increase in red blood cells level using B12, folic acid and iron supplements or with erythropoietin usage. Other methods involve the optimisation of surgical technique and the use of a machine for intraoperative blood salvage, known as "cell saver".
The aim of this study was to establish the rate for ABT during elective open abdominal aortic surgery, find parameters associated with ABT requirements, and optimise the investigators hospital's maximum surgical blood ordering schedule (MSBOS).
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients older than 18 years
- Elective open abdominal aortic surgery
- Abdominal aortic aneurysm repair
- Abdominal aortic bypass grafting for occlusive aortoiliac disease
Exclusion Criteria:
- Patients younger than 18 years
- Patients undergoing cardiac surgery
- Patients with ruptured abdominal aneurysms
- Patients undergoing endovascular aortic repair
- Patients submitted to other types of vascular surgery (i.e., carotid endarterectomy or peripheral bypass surgery)
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Transfused group (TR)
Group received allogenic blood transfusion (ABT) alongside with autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
|
During elective open aortic surgery, the autologous blood from ICS was processed and re-transfused in all patients.
However, TR group additionally received ABT.
|
Non-transfused (non-TR)
Group received only autologous blood from intraoperative cell saver (ICS) during elective open abdominal aortic surgery.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
Overall ABT requirement (in %) during elective abdominal aortic surgery with the use of ICS for intraoperative blood salvage and autologous transfusion.
|
Retrospective analysis, 6-year period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Age as the predictor of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
(years)
|
Retrospective analysis, 6-year period
|
Gender as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
male/female
|
Retrospective analysis, 6-year period
|
Body mass index (BMI) as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
BMI (kg/m2)
|
Retrospective analysis, 6-year period
|
Body surface area (BSA) as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
BSA (m²)
|
Retrospective analysis, 6-year period
|
Total blood volume as the possible predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
TBV (in liters) calculated trough Nadler's formula
|
Retrospective analysis, 6-year period
|
Hemoglobin (Hb) and hematocrit (Htc) as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
Hb (g/L) and Htc (%)
|
Retrospective analysis, 6-year period
|
Type of illness as the predictor of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
abdominal aortic aneurysm or aortoiliac occlusive disease
|
Retrospective analysis, 6-year period
|
Patient's comorbidities as the predictors of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
arterial hypertension, coronary artery disease, diabetes, atrial fibrillation, cerebrovascular incidents, chronic obstructive pulmonary disease, chronic renal insufficiency, malignancy
|
Retrospective analysis, 6-year period
|
Medications that impair coagulation and homeostasis as the predictor of higher ABT requirement
Time Frame: Retrospective analysis, 6-year period
|
acetylsalicylic acid, clopidogrel, or warfarin
|
Retrospective analysis, 6-year period
|
Postoperative duration of mechanical ventilation
Time Frame: Retrospective analysis, 6-year period
|
(hours)
|
Retrospective analysis, 6-year period
|
Length of stay (LOS)
Time Frame: Retrospective analysis, 6-year period
|
LOS in ICU (days) and overall hospital LOS (days)
|
Retrospective analysis, 6-year period
|
In-hospital mortality rate
Time Frame: Retrospective analysis, 6-year period
|
(in %)
|
Retrospective analysis, 6-year period
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Kent KC, Zwolak RM, Egorova NN, Riles TS, Manganaro A, Moskowitz AJ, Gelijns AC, Greco G. Analysis of risk factors for abdominal aortic aneurysm in a cohort of more than 3 million individuals. J Vasc Surg. 2010 Sep;52(3):539-48. doi: 10.1016/j.jvs.2010.05.090. Epub 2010 Jul 13.
- Ashworth A, Klein AA. Cell salvage as part of a blood conservation strategy in anaesthesia. Br J Anaesth. 2010 Oct;105(4):401-16. doi: 10.1093/bja/aeq244. Epub 2010 Aug 28.
- Roubinian NH, Murphy EL, Swain BE, Gardner MN, Liu V, Escobar GJ; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III); Northern California Kaiser Permanente DOR Systems Research Initiative. Predicting red blood cell transfusion in hospitalized patients: role of hemoglobin level, comorbidities, and illness severity. BMC Health Serv Res. 2014 May 10;14:213. doi: 10.1186/1472-6963-14-213.
- Bursi F, Barbieri A, Politi L, Di Girolamo A, Malagoli A, Grimaldi T, Rumolo A, Busani S, Girardis M, Jaffe AS, Modena MG. Perioperative red blood cell transfusion and outcome in stable patients after elective major vascular surgery. Eur J Vasc Endovasc Surg. 2009 Mar;37(3):311-8. doi: 10.1016/j.ejvs.2008.12.002. Epub 2008 Dec 25.
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ABT2011-2016
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Transfusion
-
Wellspect HealthCareCompletedArthroplasty, Replacement, Knee | Blood Transfusion | Blood Transfusion, AutologousPoland
-
Wellspect HealthCareCompletedBlood Transfusion | Arthroplasty, Replacement, Hip | Blood Transfusion, AutologousAustria, Netherlands, Norway, Spain
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedBlood Transfusion | Orthopedic Surgery | Orthopedic Procedures | Cardiovascular Surgical Procedure | Blood Transfusion, Autologous
-
University of Colorado, DenverCompleted
-
Diskapi Teaching and Research HospitalCompleted
-
Dartmouth-Hitchcock Medical CenterBEST research collaborativeCompletedBlood TransfusionNorway, United States, Australia, Canada, United Kingdom, Brazil
-
Perouse MedicalEclevar MedtechRecruitingChemotherapy | Blood Transfusion | Antibiotics | Parenteral Nutrition | Antiviral Drugs | Veinous | Blood Derivatives Transfusion | PMCF StudyFrance
-
National Heart, Lung, and Blood Institute (NHLBI)Completed
-
General Hospital of Ningxia Medical UniversityCompleted
Clinical Trials on Allogenic blood transfusion (ABT)
-
Wellspect HealthCareCompletedArthroplasty, Replacement, Knee | Blood Transfusion | Blood Transfusion, AutologousPoland
-
Hamad Medical CorporationSidra Medical and Research Center; World Anti-Doping Agency; Anti-Doping Lab... and other collaboratorsUnknownBlood Disease | Blood Transfusion, Autologous | Blood Doping | Blood Transfusion, HomologousQatar
-
University of AlbertaAlberta Innovates Health Solutions; University Hospital Foundation; EPICORE CentreNot yet recruitingPostoperative Hemorrhage | Postoperative Anemia | Postoperative Blood LossCanada
-
Hospital PitangueirasUnknown
-
Emory UniversityWithdrawnHematopoietic and Lymphoid Cell Neoplasm | Leukemia | Anemia | Myelodysplastic Syndrome | Aplastic Anemia | Bone Marrow FailureUnited States
-
Haukeland University HospitalDentsply Sirona Implants and ConsumablesCompleted
-
Mahidol UniversityWolf Schleinzer Stiftung zur Wissenschafts- und Bildungsförderung, GermanyCompletedSurgery | Immune Defect | Incompatible Blood TransfusionThailand
-
Oregon Health and Science UniversityNot yet recruitingTraumatic Brain Injury
-
Assistance Publique - Hôpitaux de ParisCompletedMyocardial Infarction | Anemia | Blood TransfusionSpain, France
-
Direction Centrale du Service de Santé des ArméesFloralis; TIMC-IMAGRecruitingTrauma | Coagulopathy | Acute HemorrhageFrance